High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.

Simberg N, Tiitinen A, Silfvast A, Viinikka L, Ylikorkala O

The Journal of clinical endocrinology and metabolism1 Feb 1996Cited by 20 (Europe PMC)

PMID8636283DOI10.1210/jcem.81.2.8636283PepBankPUB-08636283

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialSafety outcome
In hirsute women, bone mineral density was unaffected after the first 3 months of goserelin.
In plain wordsBone density did not change after the first 3 months of goserelin in hirsute women.
Peptide
Goserelin
Outcome
No significant changeBone mineral density
Study
n = 20
Comparator
Prestudy levels
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.6-mg implant · implant · 3 monthsAs given in this study (human).
Source sentences
Summary
After the first 3 months of trial, BMD was unaffected
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 hirsute patients with high levels of serum testosterone (T), calculated free T, androstenedione, and dehydroepiandrosterone sulfate and 19 age-matched nonhirsute normoandrogenic control women.
Summary · context
The hirsute women were treated with a GnRH agonist (goserelin, 3.6-mg implant) for 9 months. After the first 3 months of treatment, half of the patients were randomized to receive estrogen-progestin replacement therapy (HRT), and the other half served as controls.
Report a problemFND-0863628301
02HumanNon-randomized trialActivity measurement
In hirsute women, urinary collagen pyridinoline, deoxypyridinoline cross-links, and hydroxyproline increased after the first 3 months of goserelin.
In plain wordsIn hirsute women, three urinary markers of bone breakdown increased after the first 3 months of goserelin.
Peptide
Goserelin
Outcome
IncreaseUrinary bone resorption markers
Study
n = 20
Comparator
Prestudy levels
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.6-mg implant · implant · 3 monthsAs given in this study (human).
Source sentences
Summary
After the first 3 months of trial, BMD was unaffected, and the urinary output of collagen pyridinoline, deoxypyridinoline cross-links, and hydroxyproline (all markers of bone resorption) were increased
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 hirsute patients with high levels of serum testosterone (T), calculated free T, androstenedione, and dehydroepiandrosterone sulfate and 19 age-matched nonhirsute normoandrogenic control women.
Summary · context
The hirsute women were treated with a GnRH agonist (goserelin, 3.6-mg implant) for 9 months. After the first 3 months of treatment, half of the patients were randomized to receive estrogen-progestin replacement therapy (HRT), and the other half served as controls.
Report a problemFND-0863628302
03HumanNon-randomized trialActivity measurement
In hirsute women, serum carboxy-terminal telopeptide of type I collagen did not change after the first 3 months of goserelin.
In plain wordsSerum carboxy-terminal telopeptide did not change after the first 3 months of goserelin in hirsute women.
Peptide
Goserelin
Outcome
No significant changeSerum carboxy-terminal telopeptide of type I collagen
Study
n = 20
Comparator
Prestudy levels
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.6-mg implant · implant · 3 monthsAs given in this study (human).
Source sentences
Summary
but serum markers, the carboxy-terminal telopeptide of type I collagen (marker of bone resorption) and that of bone-specific alkaline phosphatase (marker of bone formation) did not change.
3 context sentences(design, population, supporting numbers)
Summary · context
The hirsute women were treated with a GnRH agonist (goserelin, 3.6-mg implant) for 9 months.
Summary · context
We studied 20 hirsute patients with high levels of serum testosterone (T), calculated free T, androstenedione, and dehydroepiandrosterone sulfate and 19 age-matched nonhirsute normoandrogenic control women.
Summary · context
The hirsute women were treated with a GnRH agonist (goserelin, 3.6-mg implant) for 9 months. After the first 3 months of treatment, half of the patients were randomized to receive estrogen-progestin replacement therapy (HRT), and the other half served as controls.
Report a problemFND-0863628303
04HumanNon-randomized trialActivity measurement
In hirsute women, serum bone-specific alkaline phosphatase did not change after the first 3 months of goserelin.
In plain wordsSerum bone-specific alkaline phosphatase did not change after the first 3 months of goserelin in hirsute women.
Peptide
Goserelin
Outcome
No significant changeBone-specific alkaline phosphatase
Study
n = 20
Comparator
Prestudy levels
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.6-mg implant · implant · 3 monthsAs given in this study (human).
Source sentences
Summary
but serum markers, the carboxy-terminal telopeptide of type I collagen (marker of bone resorption) and that of bone-specific alkaline phosphatase (marker of bone formation) did not change.
3 context sentences(design, population, supporting numbers)
Summary · context
The hirsute women were treated with a GnRH agonist (goserelin, 3.6-mg implant) for 9 months.
Summary · context
We studied 20 hirsute patients with high levels of serum testosterone (T), calculated free T, androstenedione, and dehydroepiandrosterone sulfate and 19 age-matched nonhirsute normoandrogenic control women.
Summary · context
The hirsute women were treated with a GnRH agonist (goserelin, 3.6-mg implant) for 9 months. After the first 3 months of treatment, half of the patients were randomized to receive estrogen-progestin replacement therapy (HRT), and the other half served as controls.
Report a problemFND-0863628304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.